Systematic Review of Compound Danshen Dropping Pill: A Chinese Patent Medicine for Acute Myocardial Infarction

Table 6

Analyses of secondary outcomes.

Outcomes (comparisons)	Treatment (𝑛/𝑁)	Control (𝑛/𝑁)	Weight; (%)	RR	95% CI
(1) Heart failure
(1.1) CDDP + conventional therapy versus conventional therapy
Xu and Wang 2007 [21]	3/66	12/80	32.40	0.30	[0.09, 1.03]
Guo et al. 2010 [20]	5/76	13/60	43.40	0.30	[0.11, 0.80]
Li et al. 2011 [19]	6/252	8/248	24.10	0.74	[0.26, 2.10]
Total (FEM, 𝐈^𝟐 = 0%)			100.00	0.41	[0.22, 0.75]
Sensitive analysis
Xu and Wang 2007 [21]	3/66	12/80	57.30	0.30	[0.09, 1.03]
Guo et al. 2010 [20]	5/76	13/60	42.70	0.30	[0.11, 0.80]
Total (FEM, 𝐈^𝟐 = 0%)			100.00	0.30	[0.14, 0.65]
(1.2) CDDP + conventional therapy versus placebo + conventional therapy
Li et al. 2010 [36]	5/42	4/21	100.00	0.63	[0.19, 2.09]
(1.3) CDDP + conventional therapy versus propranolol + conventional therapy
Xu and Wang 2007 [21]	3/66	11/72	100.00	0.26	[0.07, 0.99]
(2) Recurrent angina
(2.1) CDDP + conventional therapy versus conventional therapy
Guo 2010 [20]	2/76	11/60	33.40	0.14	[0.03, 0.62]
Li et al. 2011 [19]	27/252	54/248	66.60	0.49	[0.32, 0.75]
Total (REM, 𝐼^2 = 61%)			100.00	0.33	[0.10, 1.03]
(2.2) CDDP + conventional therapy versus placebo + conventional therapy
Li et al. 2010 [36]	12/42	11/21	100.00	0.55	[0.29, 1.02]
(3) Readmission
CDDP + conventional therapy versus placebo + conventional therapy
Li et al. 2010 [36]	3/42	4/21	100.00	0.38	[0.09, 1.52]